Global Behcet’s Disease Market - 2023-2030

Global Behcet’s Disease Market - 2023-2030

Global Behcet’s Disease Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.

Behcet's disease, also known as Silk Road disease, is an inflammatory disease that lasts a long time and can be brought on by vasculitis (inflammation of the blood vessels). It can harm the arteries and veins. A wide range of symptoms that differ from person to person might result from this illness. Recurrent mouth ulcers, vaginal ulcers, and eye inflammation are typical signs of behcet’s disease.

It can also result in gastrointestinal issues, joint discomfort and swelling, and skin sores in addition to these symptoms. Behcet’s disease has no known cure, but its symptoms can be controlled using drugs that lessen inflammation and regulate the immune system. Corticosteroids, immunosuppressive drugs, and medications to treat pain and other particular symptoms may all be used in the process of treatment depending on the patient's symptoms.

Market Dynamics: Drivers and Restraints

The strategies adopted by the companies

There is currently no cure for the chronic, painful disease known as behcet’s disease. Symptoms that patients frequently experience negatively affect their quality of life. By addressing this unmet medical need, therapies can improve patients' lives while setting up a potential market for pharmaceutical companies. Thus, the companies strategies employed aid to accelerate market expansion.

For instance, in May 2023, Soligenix, Inc. reported that it had signed an exclusive option contract with privately held Silk Road Therapeutics. In accordance with the terms of the option agreement, the Company is entitled to purchase a novel topical formulation of Pentoxifylline (PTX), a non-biological anti-TNF-alpha inhibitor, for the treatment of mucocutaneous ulcers in behcet’s disease patients.

Government programmes and funding for research on uncommon illnesses, such as behcet’s disease, can also have a big impact on the market. Drug development can be speed up and patient access to therapies can be improved with funding, grants, and regulatory support.

Market Dynamics: Restraint

Behcet’s disease may be constrained by a number of circumstances, making diagnosis, treatment, and research efforts challenging. For instance, the severity of the symptoms varies greatly from person to person. It might be challenging to establish standardised treatment protocols because some people may experience modest symptoms while others may suffer from serious problems.

Additionally, while there are medications to address the symptoms, for behcet’s disease. Some people might not respond well to the therapies that are available, leaving them with few options for symptom control. Lack of knowledge among the general population, medical professionals, and even some specialists may lead to a delayed or inaccurate diagnosis.

Segment Analysis

The global behcet’s disease marketis segmented based on disease type, drug class, distribution channel and region.

The PDE4 inhibitors segment from the type segment accounted for approximately 31.7% of behcet’s disease share

PDE4 inhibitors are a class of drugs that focus on the PDE4 enzyme, which is involved in the inflammatory response. These inhibitors function by preventing PDE4 from doing its task, which raises intracellular cyclic adenosine monophosphate (cAMP) levels. PDE4 inhibitors have the potential to be effective in the treatment of inflammatory illnesses, such as behcet’s disease, by enhancing cAMP levels and assisting in the regulation of the immune response and decreasing inflammation.

Moreover, according to American Behcet's Disease Association, stated that, apremilast (Otezla), an oral selective phosphodiesterase 4 (PDE4) inhibitor, is the first and only approved treatment by the US Food and Drug Administration (FDA) for oral ulcers associated with Behcet's Disease. Thus above factors helps to boost the segment growth.

Geographical Analysis

Asia Pacific accounted for approximately 38.4% of the market share in 2022

The rising prevalence of behcet's disease is expected to lead to favorable market expansion in the Asia Pacific region during the forecast period. It is frequently seen by those who live in China and Japan. Between the populations of the 30th and 45th degree latitudes, it is regularly observed. For instance, a research study published in May 2021 in the Journal of Clinical Rheumatology and Immunology reported that in East Asia, the prevalence was reported to be 16/100,000 in Japan, 35/100,000 in Korea, and 14/100,000 in China. This knowledge is expected to drive the behcet's disease market growth during the forecast period in the region.

Additionally, behcet’s disease is more widespread in the Middle East, particularly in the nations along the old Silk Road and in the Mediterranean region, where it is also common, including Turkey, Iran, Iraq, and countries in the Far East. There are 14–20 cases of the illness for every 100,000 people along the Silk Road. Turkey has the highest prevalence of BD, with 20-602/100,000. Thus, it is expected that the Middle East will dominate the market over the forecast period.

COVID-19 Impact Analysis

Healthcare systems were under pressure during the pandemic's peak in numerous countries, which disrupted routine medical care, particularly for those with behcet’s disease. The care and treatment of the condition may have been compromised by missed or cancelled appointments. The pandemic may have caused certain clinical trials and research studies on Behçet's illness to be postponed or discontinued.

This might have an effect on the creation of novel illness medicines and treatments. Patients with behcet’s disease, especially that on immunosuppressive therapy, could have had to deal with more worries about their propensity for developing a serious illness in the event that they got COVID-19. Their contacts with the healthcare system and decisions about their care may have been affected by these concerns.

Market Segmentation

By Disease Type
• Neuro-Behcet
• Ocular-Behcet
• Vasculo-Behcet

By Drug Class
• Corticosteroids
• Phosphodiesterase 4 Inhibitor
• Immunosuppressive Drugs
• Anti-gout Agents
• Topical Treatments
• Others

By Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Par Pharmaceutical, Takeda Pharmaceuticals U.S.A., Inc, Endo International plc, Pfizer Inc, Sebela Pharmaceuticals, Aark Pharmaceuticals, Janssen Pharmaceuticals, Genentech, Inc, Amgen Inc, Delphis Pharmaceutical and among others.

Why Purchase the Report?
• To visualize the global behcet’s disease market segmentation based on disease type, drug class, distribution channel and region as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of behcet’s disease market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global behcet’s disease market report would provide approximately 69 tables, 58 figures and 187 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies